Erik Kruger, MD
Ophthalmology · Kingston, PANPI 1104886332
Payments from drug & device makers
Across 180 payments — averaging $16,411 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$1.7M
- Bayer$319K
- Regeneron$278K
- Roche TCRC, Inc.$217K
- AstraZeneca$181K
- Amgen$126K
- plus $112K from 11 others
Across 6 payments — averaging $167.66 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$1K
What the payments were for
- Food & beverage$469100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 18 | $1,720,548 |
| Bayer | 31 | $318,947 |
| Regeneron | 60 | $278,294 |
| Roche TCRC, Inc. | 14 | $217,160 |
| AstraZeneca | 4 | $181,073 |
| Amgen | 5 | $126,302 |
| Kyowa Kirin, Inc. | 23 | $87,929 |
| Genentech, Inc. | 6 | $18,344 |
| Hexal AG | 1 | $5,000 |
| Regeneron Healthcare Solutions, Inc. | 5 | $104 |
| Astellas Pharma US Inc | 2 | $81 |
| AbbVie | 2 | $64 |
| Genentech USA, Inc. | 3 | $56 |
| Apellis Pharmaceuticals, Inc. | 1 | $48 |
| Alimera Sciences, Inc. | 3 | $34 |
| Biogen | 1 | $22 |
| Alcon | 1 | $15 |
How this compares
$2,954,020 in reported general payments places this provider in the 95th percentile of 920 ophthalmology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 17 | $844 |
| Diclofenac Sodium | 18 | $110 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Kingston
- Harvey ReiserKingston$660K
- Robert SzulborskiKingston$85K
- David AlmeidaErie$6.3M
- William ChristieCranberry Township$5.2M
- Carl RegilloPlymouth Meeting$3.2M
- Sunir GargPlymouth Meeting$2M
- Allen ChiangPlymouth Meeting$1.6M
- Julia HallerPhiladelphia$1.5M
- Mitchell FinemanPlymouth Meeting$1.3M
- Allen HoPlymouth Meeting$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.